Salud financiera de hoja de balance de RhoVac

Salud financiera controles de criterios 4/6

RhoVac tiene un patrimonio de los accionistas total de SEK12.8M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK33.0M y SEK20.2M respectivamente.

Información clave

Ratio deuda-patrimonio

SEK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 9.92m
Patrimonio	SEK 12.78m
Total pasivo	SEK 20.21m
Activos totales	SEK 33.00m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

Feb 12

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Aug 27

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Mar 23

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Dec 08

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK33.0M) de RHOVAC superan a sus pasivos a corto plazo (SEK20.2M).

Pasivo a largo plazo: RHOVAC no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: RHOVAC está libre de deudas.

Reducción de la deuda: RHOVAC no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RHOVAC tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: RHOVAC tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 21.8% cada año

Salud financiera de hoja de balance de RhoVac

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Recent updates

Chosa ApS completed the acquisition of RhoVac AB (NGM:RHOVAC) from M2 Asset Management AB (publ) and others in a reverse merger transaction.

RhoVac AB to Report Fiscal Year 2022 Results on Feb 10, 2023

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB to Report Q3, 2022 Results on Nov 11, 2022

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

RhoVac AB to Report Q2, 2022 Results on Aug 26, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint

Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers

No independent directors

RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer

RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers

Rhovac Announces the Completion of Patient Recruitment for the Bravac Clinical Phase Iib Study of Rv001 in Prostate Cancer

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

RhoVac AB Receives Approval to Initiate a Long-Term Follow-Up of Clinical Phase I/II Patients

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Rhovac AB Announces the Initiation of First New US Clinic in Company's Phase IIb Study

New 90-day low: kr21.00

Global Covid-19 Vaccination Roll-Out Causes Delay to Rhovac's Phase IIb Study

RhoVac AB Announces First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

New 90-day high: kr21.15

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Rhovac AB Announces That Positive Results from Rhovac's Clinical Phase I/Ii Study Published in Journal of Immunotherapy of Cancer

New 90-day low: kr16.44

RhoVac AB Announces Covid-19 pandemic affecting RhoVac's clinical phase IIb study

New 90-day high: kr20.65

RhoVac AB Announces First Patient in Treatment in Rhovac's Clinical Phase IIb Study in Sweden

RhoVac AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr16.98

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera